Dr Reddy's Laboratories Ltd Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : My first question is on the India business. You just talked about investing in nutrition OTC coming into rural areas, digital. If you could just give some color on when we would start seeing the benefit of this? And a related question on that, how much do you think we will have to spend to scale up these businesses, particularly something like OTC and nutrition businesses?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : And in terms of new launches, do we -- I just wanted to understand how many brands that we have -- do we have in the pipeline of nutrition like you mentioned, new brands would require new investments. So in that context, what is the planned launch pipeline that we have for these 2 segments?

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Understood. And second, on the API supply for our generic Vascepa launch. I just wanted to get a sense on when do you think we will get to our fair market share for the product? And do -- is API anymore or concern in terms of our ability to ramp up this product, the supplies from partners? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 27, 2021 / 12:00PM, REDY.NS - Q1 2022 Dr Reddy's Laboratories Ltd Earnings Call

Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst : Okay. And when do we think we can get to a fair market share in your assessment?